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Abstract
Objective: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of
tics in children and adolescents with Tourette’s disorder (TD).
Method:Eleven subjects (10 males) with TD (age 9–19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond
or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over
10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale
for tics (CGI-Tics) at baseline and at follow-up.
Results:The mean (SD) daily dose for aripiprazole was 4.5 3.0 mg. Mean (SD) YGTSS Global Severity scores reduced
from 61.82 13.49 at baseline to 33.73 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 7.74 at
baseline to 16.73 7.54 at end point. Mean (SD) CGI-Tic severity scores reduced from 4.45 0.52 (moderate-marked) at
baseline to 3.18 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (91%) subjects achieved 1 (‘‘very much
improved’’) or 2 (‘‘much improved’’) at end point. Most common adverse effects included appetite increase and weight gain
in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness=fatigue in 7 subjects; 1 subject
experienced akathisia and muscle cramps.
Conclusion: Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to
reduce tics; it should be further investigated as a treatment option in controlled trials.
Introduction
Tourette’s disorder (TD) is a childhood-onset neuropsychi-atric disorder characterized by multiple motor and vocal tics
(American Psychiatric Association 2000). The majority of clini-
cally referred individuals with TD also meet criteria for one or more
comorbid psychiatric disorders, including obsessive-compulsive
disorder (OCD), attention-deficit=hyperactivity disorder (ADHD),
mood disorders, and non-OCD anxiety disorders (Coffey et al.
2000). The disorder is often chronic and associated with significant
impairment.
Currently, the only medications formally approved for use in TD
are haloperidol and pimozide. However, significant side effects,
including extrapyramidal symptoms (EPS) such as acute dystonic
reactions, Parkinsonism, akathisia, and tardive dyskinesia (Shapiro
et al. 1973), have led to use of the newer atypical neuroleptics. In
recent years, the atypical neuroleptics have been used frequently to
treat tics in youth with TD; however, reports have emerged dem-
onstrating serious adverse effects, including substantial weight
gain, development of abnormal glucose and lipid metabolism,
elevated serum prolactin levels, and=or cardiac effects such as
prolongation of the QTc interval (Green 2001). a-Adrenergic ag-
onists, such as clonidine and guanfacine, are also used to treat tics
in TD, but are not formally approved for treatment. Nevertheless,
many youths with TD are unresponsive or do not tolerate the
a-adrenergic agents due to their adverse effects of sedation, dys-
phoria, and hypotension.
The aim of the study was to explore the use and tolerability of
aripiprazole as a treatment for tics in youth with TD. Aripiprazole is
an atypical antipsychotic that differs from other atypical antipsy-
chotics because it is a dopamine partial agonist and it is indicated
for treatment of schizophrenia and bipolar disorder in adults and
adolescents. Aripiprazole has been reported to be less likely to
cause weight gain in adults compared to other atypical neuroleptics
(Kolotkin et al. 2008). Recently, several case series and one open-
label study have reported on the use of aripiprazole in children and
adolescents with TD or chronic tic disorder, but to date, no con-
trolled trials have been reported (Hounie et al. 2004; Dehning et al.
2005; Kastrup et al. 2005; Murphy et al. 2005; Bubl et al. 2006;
Constant et al. 2006; Davies et al. 2006; Duane 2006; Fountoulakis
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et al. 2006; Yoo et al. 2006; Ben Djebara et al. 2008; Budman et al.
2008; Kawohl et al. 2008; Seo et al. 2008; Stenstrom and Sindo
2008; Winter et al. 2008). These case reports and open-label series
have suggested that aripiprazole at doses of 2.5–15 mg daily appears
to reduce tic severity as judged by clinician rating scales. In addition,
these studies on aripiprazole and TD primarily report efficacy
measures and sometimes report weight and body mass index (BMI).
There is very little information regarding parameters such as lipid
profiles, prolactin levels, and other blood abnormalities. We report
here a new prospective, open-label safety and tolerability study of
aripiprazole that incorporates these measures, including dosing,
tolerability, and treatment response in 11 children and adolescents
with TD.
Methods
Subjects
Design of the study was an investigator initiated, prospective, 10
week, open-label, safety and tolerability study of patients who met
Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
text revision (DSM-IV-TR) (American Psychiatric Association
2000) criteria for TD. Subjects were recruited through the Institute
for Tourette’s and Tic Disorders, referrals from local professionals,
and the Tourette Syndrome Association. All subjects were evalu-
ated with a comprehensive medical and psychiatric assessment by
the senior author with expertise in the diagnosis and treatment of
Tourette’s disorder. All subjects had been treated in the past with
conventional tic medications, including a-adrenergic agonists and
typical or atypical neuroleptics.
Recruitment of subjects occurred between September, 2005 and
August, 2008. Twenty-five subjects were screened for the study,
and 14 were screen failures as a result of failure to meet inclusion
and=or exclusion criteria. Specific reasons for screen failures in-
cluded medical contraindication, complications with medical his-
tory, success on other medication, clinical concerns with ADHD
(not TD), aripiprazole prescribed in the past with intolerable side
effects, patient was not interested, or the patient did not have an
adequate trial of clonidine.
Subjects were eligible for inclusion if they met the following
inclusion criteria: (1) Age 7–18 years of age (inclusive) when in-
formed consent was obtained; (2) met full DSM-IV-TR diagnostic
criteria for TD or chronic motor tic disorder by clinical interview on
examination by a physician investigator, and confirmed by Kiddie
Schedule for Affective Disorders and Schizophrenia for School-
Age Children–Present and Lifetime Version (K-SADS-PL)
(Kaufman et al. 1997); (3) had failed to respond or been unable to
tolerate an adequate trial, as determined by the investigator, of
clonidine, guanfacine, or neuroleptic medication in the past; (4) tics
were causing significant distress or impairment, as determined by
parent=subject and principal investigator, on current treatment
regimen; (5) no significant abnormalities in laboratory results, in-
cluding serum chemistries, hematology, and urinalysis; (6) able to
swallow pills; (7) had normal intelligence in the judgment of the
investigator.
Subjects were excluded from the study if they met any of the
following exclusion criteria: (1) Organic brain disease such as
traumatic brain injury residua; (2) met criteria for mental retarda-
tion as defined by the DSM-IV-TR; (3) history of seizure disorder
(other than febrile seizure); (4) history of Sydenham’s chorea; (5)
autism, schizophrenia, other psychotic disorder, or bipolar disorder;
(6) primary diagnosis of a major mood disorder that required on-
going psychiatric treatment; (7) neurological disorder other than a
tic disorder; (8) at least one explosive outburst per week, or four
explosive outbursts during a 1-month period of time; (9) a major
medical illness; (10) females of child bearing age unwilling to use
birth control or who were pregnant, as determined by serum
pregnancy test at baseline assessment, or lactating; (11) past or
current history of substance dependence and=or a current history of
substance abuse or who fail baseline urine toxicology screen; (12)
any clinically significant abnormal laboratory results at baseline
screening, including electrocardiogram (EKG) or blood tests; and
(13) history of ongoing or previously undisclosed child abuse.
Concomitant psychotropic medications for comorbid disorders
were allowed if the agent(s) and dose(s) had been stable for at least
1 month prior to treatment and were held constant during the entire
period of study observation. Subjects were allowed to enroll and
cross taper previous tic medication if it had provided at least some
therapeutic benefit in the past, but their tics were still causing sig-
nificant distress or impairment at the time of assessment.
Eleven subjects (10 males) were enrolled in the study. Subjects
ranged in age from 9 to 19 years; parents provided written informed
consent for use of aripiprazole for subjects less than 18 years, and
subjects age 18 or older provided their own written consent. All
subjects less than age 18 provided assent. The study protocol was
approved by the New York University Institutional Review Board
(IRB).
Procedures
All subjects underwent comprehensive medical and psychiatric
assessment at baseline, which included physical examination, serum
hematology and chemistry evaluation, and electrocardiograms.
Lifetime diagnoses were established using the K-SADS-PL
(Kaufman et al. 1997), a semistructured diagnostic interview ad-
ministered by the principal investigator and senior author. All
laboratory data were reviewed by the senior author and had to be
within normal limits before initiation of treatment.
Outcome measures
Symptom severity was assessed by the principal investigator.
Tic severity was assessed at pretreatment baseline, at weekly or
biweekly intervals during the study, and at 10 weeks posttreatment
using the Yale Global Tic Severity Scale (YGTSS) (Leckman et al.
1989) and the Clinical Global Impressions Scale for tics scale
(CGI-Tics) (Berk et al. 2008), the primary outcome measures.
Operational definition of CGI-Tics severity was as follows: (1)
Normal or no tics at all; (2) borderline, tics may or may not be
present; (3) mild, observable motor and=or vocal tics that may or
may not be noticed, would not call attention to the individual, and
are associated with no distress or impairment; (4) moderate, ob-
servable motor and=or vocal tics that would always be noticed,
would call attention to the individual, and may be associated with
some distress or impairment; (5) marked, exaggerated motor and=
or vocal tics that are disruptive, would always call attention to the
individual, and are always associated with significant distress or
impairment; (6) severe, extremely exaggerated motor and=or vocal
tics that are disruptive, would always call attention to the individ-
ual, and are associated with injury or inability to carry out daily
functions.
Secondary outcome measures were administered at pretreat-
ment, weekly, or biweekly intervals during the study, and at 10
weeks posttreatment and included the Children’s Global Assess-
ment Scale (C-GAS) administered by the principal investi-
gator, Attention Deficit Hyperactivity Disorder Rating Scale
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(ADHD-RS) parent rating version, Children’s Depression Rating
Scale Revised (CDRS) administered by the principal investigator,
Clinical Global Impressions Scale for Obsessive Compulsive
Disorder (CGI-OCD), Clinical Global Impressions Scale for
Attention-Deficit Hyperactivity Disorder (CGI-ADHD), Children’s
Yale-Brown Obsessive Compulsive Scale (CY-BOCS) adminis-
tered by the principal investigator, and the Multidimensional An-
xiety Scale for Children (MASC), a self-report scale.
Dosing and visit schedule
All medication and treatment decisions were made by the study
principal investigator. Previous tic medication was tapered and
discontinued during the screening and washout period between visit
1 (Screening) and visit 2 (Medication Initiation). Most subjects
were off clonidine or guanfacine for at least 2 weeks, and typical or
atypical neuroleptics for at least 4 weeks prior to starting study
medication. However, if it was clinically unfeasible, in the judg-
ment of the investigator, for the subject to remain off previous tic
medication for the duration of the washout phase, aripiprazole
could be cross-tapered after visit 2 during the first 2–4 weeks of
treatment. Clinically unfeasible was defined as, in the judgment of
investigator and parents, the subject’s tics would be highly likely to
cause significant distress or impairment during a washout phase.
Subjects on medication for a comorbid condition (such as a
stimulant for ADHD or a selective serotonin reuptake inhibitor
[SSRI] for OCD) could remain on the medication during the study,
but agreed to remain on the same dosage throughout the duration of
the study. One subject was receiving citalopram and one was on
escitalopram for the duration of the study.
Aripiprazole was initiated at doses of 1.25 mg for preadolescents
or 2.5 mg for adolescents daily. Subjects between 25 and 50 kg
were started on 1.25 mg=day and between 50 and 70 kg were started
on 2.5 mg=day. Subjects were flexibly titrated by 1.25–2.5 mg
every 5–7 days as tolerated and clinically indicated. Subjects were
assessed at weekly intervals during the first 6 weeks and then bi-
weekly for the second 4 weeks.
Dosage reductions were allowed at any time throughout the trial
for potential adverse events of at least moderate severity. Antic-
holinergic medication was allowed for subjects who experienced
extrapyramidal side effects.
Safety measures
Potential adverse effects were discussed in detail prior to initi-
ation of treatment with aripiprazole, and were closely monitored at
each office visit by review of systems using the Safety Monitoring
Uniform Report Form (SMURF) (Greenhill et al. 2004). In addition
to the SMURF, safety assessments included vital signs, weight,
BMI, waist circumference, Abnormal Involuntary Movement Scale
(AIMS), clinical hematological and chemistry laboratory measures,
and electrocardiograms. A physical exam was performed on all
subjects at baseline and the last visit. Clinical laboratory measures
included qualitative urine human chorionic gonadotropin (hCG)
(for females), conjugated bilirubin and prolactin panel, comprehen-
sive metabolic panel and lipid profile, and complete blood count
(CBC) with differential. Adverse effects were monitored and
documented at all postbaseline visits.
Analytic methods
Study data were examined with respect to distribution, outliers,
and missing values. The demographic and clinical characteristics of
samples are described in terms of means, standard deviations,
range, and proportions as needed. Appropriate transformations are
applied where the data are not normally distributed.
This study was an open-label design, with each subject con-
tributing baseline and posttreatment measures. Therefore, Wilcoxon
signed rank tests for paired data were used to compare pretreatment
(baseline) and posttreatment (end point) scores on all primary
outcome measures. Exploratory analyses were conducted to com-
pare baseline and end-point scores on measures of global func-
tioning, and psychiatric comorbidity. Significance is judged at level
p¼ 0.05, two-sided; p values are reported unadjusted for multiple
comparisons. Analyses were performed using SPSS version 16.
Results
Description of sample
Sociodemographic characteristics of the study sample are de-
scribed in Tables 1 and 2. Subjects included 10 males (91%) and 1
female (9%); age range was 9–19 years old with mean (SD)
13.36 3.33 years. High rates of psychiatric comorbidity were
observed in these subjects: 9 (82%) met lifetime criteria for ADHD,
3 (27%) for OCD, and 2 (18%) for non-OCD anxiety disorders. One
subject (9%) met lifetime criteria for major depressive disorder.
Two (18%) subjects took other psychotropic medication (citalopram
and escitalopram, respectively) for their comorbid psychiatric
disorders during the study, but the dosages of these medications
remained stable during the study.
Dosing, range, and compliance
The dose range for aripiprazole was 1.25–13.75 mg daily; mean
(SD) daily dose was 4.5 3.0 mg. Treatment duration was ap-
proximately 10 weeks (mean 78 days, SD 21.82) with dosing
titrated to therapeutic range within 4–6 weeks. The entire sample
had a mean medication compliance rate of 93% (SD 9.90) that
ranged from 75% to 109%.
Five subjects (45%) were cross-tapered from previous tic med-
ication to aripiprazole during the first 2–4 weeks of the study; that
is, they began treatment with aripiprazole while taking their pre-
vious tic medication which was tapered and discontinued. Two
subjects (18%) were cross-tapered from clonidine, 2 subjects (18%)
were cross-tapered from haloperidol, and 1 subject (9%) was cross-
tapered from risperidone. Six subjects (55%) were on no medica-
tion and received aripiprazole only during the trial. Four subjects
(36%) received benztropine and 1 (9%) lorazepam for extrapyra-
midal adverse effects during the study.
Table 1. Demographics and Comorbid Diagnoses (N¼ 11)
N (%)
Males 10 (91%)
Females 1 (9%)
Comorbid diagnosis
ADHD 9 (82%)
OCD 3 (27%)
MDD 1 (9%)
Non-OCD Anxiety 2 (18%)
Mean age (range) 13.36 (9–19)
Abbreviations: ADHD¼Attention-deficit=hyperactivity disorder; OCD¼
obsessive-compulsive disorder; MDD¼major depressive disorder.
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Primary outcome measures: Tic effects
Mean (SD) pretreatment (baseline) YGTSS Global Severity
score (61.82 13.49) (marked) declined significantly to end point
(33.73 15.18; p¼ 0.003) (mild) (Table 3) while YGTSS Total Tic
scores also declined significantly from baseline (28.18 7.74)
(moderate) to end point (16.73 7.54; p¼ 0.003) (minimal). Mean
(SD) CGI-Tic severity scores reduced significantly from
4.45 0.52 (moderate-marked) at baseline to 3.18 0.60 (mild) at
end point ( p¼ 0.004). Ten (91%) subjects achieved CGI-Tic Im-
provement scores of 1 (‘‘very much improved’’) or 2 (‘‘much im-
proved’’) at end point (Fig. 1).
Outcome measures were explored for patients with severe TD
and those with nonsevere TD. Patients with severe TD were defined
as those that had scores of 25 or higher on the YGTSS total tic
subscale, whereas those who were defined as having nonsevere TD
had scores of 24.99 or lower. Patients with severe TD had mean
(SD) pretreatment (baseline) YGTSS Global Severity scores
(69.14 5.90) (marked) that declined significantly to end point
(40.71 13.01; p¼ 0.018) (moderate) (Table 4), whereas YGTSS
Total Tic scores also declined significantly from baseline (33.43
2.30) (moderate) to end point (20.43 6.35; p¼ 0.017) (minimal).
Mean (SD) CGI-Tic severity scores reduced significantly from
4.57 0.54 (moderate-marked) at baseline to 3.43 0.54 (mild-
moderate) at end point ( p¼ 0.023).
Patients with nonsevere TD had mean (SD) pretreatment
(baseline) YGTSS Global Severity scores (49.00 13.88) (mod-
erate) that declined to end point (21.50 10.79; p¼ 0.068) (mild)
(Table 5), while YGTSS Total Tic scores also declined from
baseline (19.00 10.25) (minimal) to end point (10.25 4.57;
p¼ 0.068) (minimal). Mean (SD) CGI-Tic severity scores reduced
significantly from 4.25 0.50 (moderate-marked) at baseline to
2.75 0.50 (borderline-mild) at end point ( p¼ 0.063). Differences
between baseline and end-point YGTSS Global Severity scores,
YGTSS Total Tic scores, and CGI-Tic severity scores only trended
toward significance in these patients with nonsevere TD. Effect
sizes for all primary outcome measures ranged from 0.47 to 0.66
(Tables 3–5).
Secondary outcome measures: Effects on
global assessment and comorbid disorder severity
Exploratory analyses were conducted to assess effects of ar-
ipiprazole on secondary outcomes, including OCD (CYBOCS),
ADHD (ADHD-RS), C-GAS, depression (CDRS), and anxiety
(MASC), and are shown in Table 6.
Overall functioning as measured on the C-GAS showed signif-
icant improvement with an increase from mean (SD) C-GAS
score at pretreatment (baseline) of 53.36 4.03 (some noticeable
problems) to end point to 60.64 4.63; p¼ 0.004 (some problems).
There was a significant decrease from baseline to end point in
mean (SD) ADHD-RS inattention scores (14.80 6.30 vs.
11.20 6.89; p¼ 0.035), ADHD-RS hyperactivity-impulsivity
scores (13.60 7.65 vs. 9.30 6.70; p¼ 0.007), and ADHD-RS
total scores (28.40 12.80 vs. 20.50 11.58; p¼ 0.007). CGI-
ADHD scores reduced from baseline to end point (mild to border-
line ill) (3.36 0.92 vs. 2.70 1.25; p¼ 0.063), but this was not
statistically significant.
There was a significant decrease from baseline to end point
in mean (SD) CGI-OCD scores (2.55 0.93 vs. 2.00 0.94; p¼
0.034) (borderline ill). There was a significant reduction in mean
(SD) CY-BOCS Total score (8.18 6.15 vs. 3.45 3.05; p¼
0.035) and mean (SD) CY-BOCS Obsession scores (3.91 3.30
vs. 1.09 1.81; p¼ 0.035) but no significant reduction in CY-BOCS
Compulsion scores (4.27 3.04 vs. 2.36 2.50; p¼ 0.085) from
baseline to end point.
There were no significant changes in measures of anxiety
(MASC) and depression (CDRS-R) from baseline to end point.
Mean (SD) baseline MASC Total score was 45.78 17.02 versus
47.86 12.06 end point ( p¼ 0.917); mean (SD) baseline CDRS-
R score was 39.09 8.88 versus 35.82 5.46 at end point ( p¼
0.123). Effect sizes for all secondary outcome measures ranged
from 0.030 to 0.608 (Table 6).
Adverse effects
The majority of subjects tolerated aripiprazole well. In most
cases, adverse effects emerged when the dose was increased in an
attempt to target symptoms that did not respond to lower dosage.
Titrations were made in 1.25- to 2.5-mg increments only.
Most common adverse effects were reported to be mild and
included appetite increase and weight gain in 7 subjects and extra-
pyramidal side effects (EPS) (muscle, bone, or joint pain conditions
Table 2. Concomitant Medications: Subjects Crossed Over
from Previous Tic Medications to Aripiprazole (N¼ 5)
Drug
Number of participants
on drug
Haloperidol 2
Clonidine 2
Risperidone (only for first week) 1
Table 3. Tic Effects in TD Subjects (N¼ 11)
Rating Baseline (mean SD) End point (mean SD) Difference (mean SD) Effect size (r) p value
CGI-Tic
Severity 4.45 (0.52) 3.18 (0.60) 1.27 (0.65) 0.616 0.004
YGTSS
Motor tic 15.82 (4.40) 9.73 (2.76) 6.09 (4.41) 0.598 0.005
Vocal tic 12.36 (7.10) 7.00 (5.76) 5.36 (4.57) 0.569 0.008
Total tic 28.18 (7.74) 16.73 (7.54) 11.45 (6.23) 0.626 0.003
Global Severity 61.82 (13.49) 33.73 (15.18) 28.09 (11.83) 0.626 0.003
Abbreviations: TD¼Tourette’s disorder; SD¼ standard deviation; CGI-Tic¼Clinical Global Impressions Scale for tics; YGTSS¼Yale Global Tic
Severity Scale.
626 LYON ET AL.
FIG. 1. (A) The mean CGI-Tic Severity scores from baseline to end point (N¼ 11). (B) The mean YGTSS Total Tic scores from
baseline to end point (N¼ 11). (C) The mean YGTSS Global Severity scores from baseline to end point (N¼ 11). Error bars represent
the standard deviation (2.0), in these measurements. CGI-Tic Severity¼Clinical Global Impressions–Tic Severity; YGTSS¼Yale
Global Tic Severity Scale.
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on the SMURF) in 10 subjects (Table 7). Other common adverse
effects were headaches, experienced by all 11 patients, and
tiredness=fatigue in 8 subjects (Table 7). One subject (patient 8;
see tables in Appendix) dropped out before 10 weeks due to
akathisia and muscle cramps unresponsive to dosage reduction and
anticholinergic medication.
Weight
Overall, there was not a significant difference between the means
(SD) of weight in pounds at baseline (131.54 52.65 vs. 133.69
55.88; p¼ 0.286) and at end point. Subjects gained an average of
2.16 pounds (SD 8.63) over the course of the study; the 6 subjects
who reported weight gain as an adverse event gained 4.3 pounds
(SD 11.24) (Table 8). The data were stratified by pubertal status as
shown in Table 8. Stratification of subjects by developmental stage
(preadolescents age 7–11; and adolescents age 12–19) had no effect
on overall findings in this small number of subjects. It is important to
note that the 5 subjects (45%) who were cross-tapered from previous
tic medications, including clonidine, haloperidol, and risperidone, to
aripiprazole during the first half of the study began with a mean
weight of 130.80 57.23 and ended with a mean weight of
128.4 60.83 for an average weight loss of 2.4 pounds 7.76
( p¼ 0.893) during the study. Those 3 subjects (27%), who under-
went cross-taper from previous neuroleptic medications, including
haloperidol and risperidone, to aripiprazole during the first half of the
study, began with a mean weight of 146.0 75.29 and ended with a
mean weight of 141.17 82.27 for an average weight loss of 4.83
pounds 9.88 ( p¼ 0.593) during the study.
Weights of the 6 patients treated only with aripiprazole during
the study are shown in Fig. 2. It is notable that they began with a
baseline mean weight of 132.15 54.07 and ended with a mean
weight of 138.10 56.86 for an average weight gain of 5.95
pounds 7.93 ( p¼ 0.116).
Vital signs and laboratory measures
There were no significant differences between baseline and end
point in vital signs or any laboratory measurements including heart
rate, blood pressure, hematology, lipid profiles, glucose, or blood
chemistries, other than a very slight but significant increase in
chloride (102.8 0.98 vs. 104.0 2.16; p¼ 0.031). There was a
significant decrease in prolactin (15.1 11.85 vs. 5.8 5.89;
p¼ 0.037) from baseline to end point (see tables in Appendix). This
decrease was observed in 80% of the subjects regardless of whether
they were cross-tapered from a typical neuroleptic, such as halo-
peridol, or atypical neuroleptic, such as risperidone, to aripiprazole.
There were no significant changes in EKGs between baseline and
endpoint (Table 9).
Discussion
Results of this prospective, open-label, safety and tolerability
study suggest that aripiprazole was beneficial in reduction of tics in
a small sample of children and adolescents with TD who had failed
to respond or been unable to tolerate previous tic treatment. Ex-
ploratory analyses revealed beneficial effects on global function-
ing, ADHD symptoms and OCD symptoms. Mean dose was in the
low range when compared to the typical dose range of 15–30 mg
used to treat schizophrenia and bipolar disorder. Most subjects
tolerated the medication well.
Adverse effects were generally manageable. In this sample, 1
subject discontinued treatment due to the emergence of intolerable
akathisia unresponsive to dosage reduction or to anticholinergic
medication. Interestingly, this subject had been treated for several
years with moderate doses of haloperidol (3–4 mg); this experience
may have rendered him less responsive to a D2 partial agonist after
relatively long exposure to a potent D2 antagonist. Treatment with
haloperidol may have also sensitized his receptors to extrapyra-
Table 4. Tic Effects in TD Subjects with Severe YGTSS Total Tic Scores at Visit 1 (N¼ 7)
Rating Baseline (mean SD) End point (mean SD) Difference (mean SD) Effect size (r) p value
CGI-Tic
Severity 4.57 (0.54) 3.43 (0.54) 1.14 (0.69) 0.607 0.023
YGTSS
Motor tic 17.00 (3.22) 11.29 (1.89) 5.71 (4.07) 0.587 0.028
Vocal tic 16.43 (2.44) 9.14 (5.61) 7.29 (4.35) 0.634 0.018
Total tic 33.43 (2.30) 20.43 (6.35) 13.00 (7.19) 0.637 0.017
Global Severity 69.14 (5.90) 40.71 (13.01) 28.43 (12.43) 0.632 0.018
Abbreviations: TD¼Tourette’s disorder; YGTSS¼Yale Global Tic Severity Scale; SD¼ standard deviation; CGI-Tic¼Clinical Global Impressions
Scale for tics.
Table 5. Tic Effects in TD Subjects with Nonsevere YGTSS Total Tic Scores at Visit 1 (N¼ 4)
Rating Baseline (mean SD) End point (mean SD) Difference (mean SD) Effect size (r) p value
CGI-Tic
Severity 4.25 (0.50) 2.75 (0.50) 1.50 (0.58) 0.657 0.063
YGTSS
Motor tic 13.75 (5.91) 7.00 (1.63) 6.09 (4.41) 0.646 0.068
Vocal tic 5.25 (7.09) 3.25 (4.27) 5.36 (4.57) 0.474 0.180
Total tic 19.00 (3.56) 10.25 (4.57) 11.45 (6.23) 0.646 0.068
Global Severity 49.00 (13.88) 21.50 (10.79) 28.09 (11.83) 0.646 0.068
Abbreviations: TD¼Tourette’s disorder; YGTSS¼Yale Global Tic Severity Scale; SD¼ standard deviation; CGI-Tic¼Clinical Global Impressions
Scale for tics.
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midal effects. There were no other notable features in this indi-
vidual that could explain the intolerable akathisia.
The frequency of extrapyramidal side effects in this sample of
children with TD appears to be somewhat higher than expected,
compared with the frequency of such symptoms reported in studies
of adults with schizophrenia (Marder et al. 2003). However,
given aripiprazole’s partial dopamine agonist–antagonist effects,
and the putative therapeutic mechanism of action involving D2
receptor blockade, it is possible that youths with TD, with cortico-
striato-thalamic-cortical tract disinhibition, may be particularly
vulnerable to extrapyramidal side effects of this medication.
In our series, 7 (64%) of 11 subjects experienced appetite in-
crease and weight gain during treatment, although the weight
change did not reach statistical significance. This trend was a some-
what unexpected finding, because previous studies using ar-
ipiprazole monotherapy for treatment of schizophrenia in adults
resulted in a modest weight loss over an 8-week study duration
(Casey et al. 2003). However, more recent studies involving chil-
dren have suggested that children are more likely to experience
metabolic effects of aripiprazole than adults (Correll 2008).
Limitations
Some limitations of this study design must be taken into account.
Regarding our sample, all subjects had failed to respond or been
unable to tolerate previous tic medications, so they could be con-
sidered to have unique or treatment-refractory symptoms. Fur-
thermore, this was a small sample of subjects treated within a
specialty program, and ascertainment bias is possible that could
reduce the generalizability of our findings. With regard to meth-
odology, this was an open-label study, so we did not have a com-
parison group nor were we blinded to treatment. Open-label trials
are susceptible to non-medication-related effects, including pla-
cebo response and response to more frequent visits with the doctor
as part of the trial. It is important to note that the treatment and
assessments(usingsystematic,standardizedratings)wereperformed
by several investigators, but they always included the principal
investigator (B.J.C.).
Because two of our subjects were taking concomitant medica-
tion for psychiatric comorbid disorders, we cannot rule out drug
interactions as contributing to adverse effects observed, nor can we
exclude the possibility that particular concomitant medication
combinations might be contributing to synergism or additive
therapeutic effects.
Despite these limitations, findings in our exploratory study indi-
cate that aripriprazole may be a potentially beneficial and tolerable
treatment for tics inchildrenandadolescentswithTD.Oneadditional
open-label aripiprazole study published recently has also reported a
reduction in tics with aripiprazole in children and adolescents with
TD or chronic tic disorder (Seo et al. 2008). The mean dose in our
Table 6. Assessment of Global and Comorbid Disorders (N¼ 11)
Baseline mean
(SD)
Baseline
range
End-point
mean (SD)
End-point
range
Difference
mean (SD)
Effect size
(r) p value
C-GAS 53.36 (4.03) 48–60 60.64 (4.63) 52–65 7.27 (4.92) 0.608 0.004
ADHD-RS
Inattention 14.80 (6.30) 0–24 11.20 (6.89) 0–22 3.60 (3.92) 0.471 0.035
Hyperactivity-Impulsivity 13.60 (7.65) 1–22 9.30 (6.70) 0–18 4.30 (2.67) 0.599 0.007
Total 28.40 (12.80) 1–41 20.5 (11.58) 1–36 7.90 (5.36) 0.599 0.007
CDRS-R 39.09 (8.88) 30–61.5 35.82 (5.46) 30–49.5 3.27 (5.94) 0.329 0.123
CGI-OCD 2.55 (0.93) 1–4 2.00 (0.94) 1–3 0.60 (0.70) 0.474 0.034
CGI-ADHD 3.36 (0.92) 1–4 2.70 (1.25) 1–4 0.60 (0.84) 0.415 0.063
CY-BOCS
Obsession 3.91 (3.30) 0–11 1.09 (1.81) 0–6 2.82 (3.82) 0.451 0.035
Compulsion 4.27 (3.04) 0–10 2.36 (2.50) 0–8 1.91 (3.05) 0.367 0.085
Total 8.18 (6.15) 0–21 3.45 (3.05) 0–9 4.73 (6.15) 0.448 0.035
MASC total score 45.78 (17.02) 19–75 47.86 (12.06) 30–57 1.00 (16.19) 0.030 0.917
Abbreviations: C-GAS¼Children’s Global Assessment Scale; CDRS-R¼Children’s Depression Rating Scale, Revised; CGI-OCD¼Clinical Global
Impressions Scale for Obsessive Compulsive Disorder; CGI-ADHD¼Clinical Global Impressions Scale for Attention-Deficit Hyperactivity Disorder;
CY-BOCS¼Children’s Yale-Brown Obsessive Compulsive Scale; MASC¼Multidimensional Anxiety Scale for Children; ADHD-RS¼Attention
Deficit Hyperactivity Disorder Rating Scale.
Table 7. Adverse Effects (SMURF) (N¼ 11)
Type of adverse effects reported
Subjects reported
N (%)
Frequency of adverse
effect N
Frequency possibly relateda
to study drug N (%)
Headache 11 (100%) 34 1 (3%)
Muscle, bone, or joint pain=condition 10 (91%) 31 18 (56%)
Appetite increase=weight gain 7 (64%) 27 25 (93%)
Stomach discomfort 9 (82%) 26 7 (27%)
Tiredness=fatigue 8 (73%) 23 19 (83%)
Dizziness 9 (82%) 18 11 (61%)
Appetite decrease=weight loss 6 (55%) 12 10 (85%)
Drowsiness=sedation 7 (64%) 13 10 (77%)
Dry mouth 4 (36%) 10 10 (100%)
aPossibility as determined by principal investigator.
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Table 8. Effects on Height and Weight
Baseline
mean (SD)
Baseline
range
End-point
mean (SD)
End-point
range
Difference
mean (SD)
Effect
size (r) p value
Whole sample, n¼ 11
Weight (pounds) 131.54 (52.65) 73.00–232.00 133.69 (55.88) 71.50–236.0 2.16 (8.63) 0.227 0.286
BMI 22.69 (5.89) 15.26–35.27 22.91 (6.55) 14.59–36.41 0.22 (1.48) 0.085 0.689
Height (inches) 62.97 (6.97) 53.10–78.70 63.20 (7.35) 53.50–81.00 0.23 (.93) 0.186 0.383
Waist (inches) 32.77 (7.94) 25.00–46.00 32.50 (7.43) 25.00–46.00 0.27 (2.13) 0.181 0.498
Preadolescents (age 6–12), n¼ 6
Weight (pounds) 96.82 (16.04) 73.0–114.00 96.08 (14.57) 71.50–114.00 0.73 (9.21) 0.091 0.753
BMI 20.35 (4.34) 15.26–27.92 20.16 (4.47) 14.59–28.00 0.18 (1.47) 0.091 0.753
Height (inches) 58.06 (2.65) 53.10–61.00 58.18 (2.32) 53.50–59.70 0.12 (.81) 0.182 0.527
Waist (inches) 27.23 (3.15) 25.00–31.90 27.75 (2.75) 25.00–31.00 0.53 (2.36) 0.651 1.00
Adolescents (13–18), n¼ 5
Weight (pounds) 173.20 (51.29) 104.00–232.00 178.82 (53.61) 109.50–236.00 5.62 (7.26) 0.554 0.080
BMI 25.50 (6.72) 18.07–35.27 26.21 (7.57) 18.79–36.41 0.71 (1.50) 0.343 0.279
Height (inches) 68.86 (5.76) 63.60–78.70 69.22 (6.72) 64.00–81.00 0.36 (1.14) 0.058 0.854
Waist (inches) 40.17 (5.53) 35.00–46.00 38.83 (7.01) 32.00–46.00 1.33 (1.53) 0.655 0.109
Abbreviations: SD¼Standard deviation; BMI¼ body mass index.
FIG. 2. Weights (pounds) of patients only on aripiprazole (n¼ 6). The weights are shown plotted weekly for each of the 6 patients that
were not on any other antipsychotic medications and were only treated with aripiprazole during the study. There was no significant
overall weight gain noted.
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study (4.5 3.0 mg) is less than that reported in this and other prior
studies. Taken together, these studies suggest that relatively low-
dose aripiprazole is beneficial in reduction of tic symptoms in
children and adolescents with TD and chronic tic disorders.
Because both studies had an open-label design, future controlled
studies are indicated in TD. To date, there are several controlled
trials that have demonstrated the efficacy of typical neuroleptics
(haloperidol and pimozide) and atypical neuroleptics (risperidone)
for the treatment of TD (Sallee et al. 1997; Bruggeman et al. 2001;
Pringsheim and Marras 2009), although these medications have
also been shown to have adverse effects such as weight gain and
extrapramidal symptoms. Given the relatively neutral side-effect
profile observed in this and other open-label studies of aripiprazole,
aripiprazole could be considered as an additional treatment option.
However, definitive evidence concerning efficacy, effectiveness,
and adverse effects profile of aripiprazole awaits controlled com-
parative studies.
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Appendix: Dosage Titrations
Patient 4
Visit Number Weight (lbs) Drug Dosage Prolactin
1 188.00 8.60
2 192.00 Aripiprazole 1.25 mg
3 191.00 Aripiprazole 2.5 mg
4 194.50 Aripiprazole 5 mg
5 198.00 Aripiprazole 5 mg
6 199.50 Aripiprazole 6.25 mg
7 195.50 Aripiprazole 6.25 mg
8 204.80 Aripiprazole 7.5 mg 7.90
Patient 2
Visit Number Weight (lbs) Drug Dosage Prolactin
1 104.00 7.10
2 104.70 Aripiprazole 2.5 mg
3 105.00 Aripiprazole 2.5 mg
4 106.00 Aripiprazole 2.5 mg
5 106.00 Aripiprazole 2.5 mg
6 107.00 Aripiprazole 2.5 mg
7 107.50 Aripiprazole 2.5 mg
8 109.50 Aripiprazole 2.5 mg 15.30
Patient 3
Visit Number Weight (lbs) Drug Dosage Prolactin
1 85.90 10.10
2 84.00 Aripiprazole 1.25 mg
3 85.00 Aripiprazole 2.5 mg
4 89.00 Aripiprazole 2.5 mg
5 91.00 Aripiprazole 2.5 mg
6 92.00 Aripiprazole 3.75 mg
7 96.50 Aripiprazole 3.75 mg
8 99.00 Aripiprazole 5 mg 0.60
Patient 1
Visit Number Weight (lbs) Drug Dosage Prolactin
1 203.00 5.00
2 203.94 Aripiprazole 2.5 mg
3 204.50 Aripiprazole 5 mg
4 204.40 Aripiprazole 6.25 mg
5 207.00 Aripiprazole 8.75 mg
6 208.00 Aripiprazole 11.25 mg
7 207.00 Aripiprazole 11.25 mg
8 208.30 Aripiprazole 13.75 mg 3.00
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Patient 8
Visit Number Weight (lbs) Drug Dosage Prolactin
1 104.00 Clonidine 0.2 mg 6.90
2 104.50 Aripiprazole 1.25 mg,
Clonidine 0.125 mg
3 105.50 Aripiprazole 1.25 mg,
Clonidine 0.125 mg
4 104.50 Aripiprazole 1.25 mg,
Clonidine 0.125 mg
5 104.50
Patient 11
Visit Number Weight (lbs) Drug Dosage Prolactin
1 114.00 Risperidone 1 mg 24.20
2 108.00 Aripiprazole 1.25 mg,
Risperidone 0.5 mg
3 107.00 Aripiprazole 2.5 mg
4 104.00 Aripiprazole 2.5 mg
5 102.00 Aripiprazole 2.5 mg
6 101.50 Aripiprazole 3.75 mg
7 99.00 Aripiprazole 3.75 mg
8 98.50 Aripiprazole 3.75 mg 0.20
Patient 6
Visit Number Weight (lbs) Drug Dosage Prolactin
1 73.00 Pimozide 3 mg 46.80
2 77.00 Aripiprazole 1.25 mg
3 72.00 Aripiprazole 2.5 mg
4 72.00 Aripiprazole 6.25 mg
5 72.00 Aripiprazole 7.5 mg
6 72.00 Aripiprazole 8.75 mg
7 70.00 Aripiprazole 8.75 mg
8 71.50 Aripiprazole 8.75 mg 3.30
Patient 7
Visit Number Weight (lbs) Drug Dosage Prolactin
1 92.00 Haloperidol 2 mg 13.80
2 93.50 Aripiprazole 1.25 mg,
Haloperidol 2 mg
3 95.50 Aripiprazole 2.5 mg,
Haloperidol 0.5 mg
4 92.50 Aripiprazole 3.75 mg
5 91.00 Aripiprazole 5 mg
6 90.50 Aripiprazole 6.25 mg
7 92.00 Aripiprazole 6.25 mg
8 89.00 Aripiprazole 10 mg 1.60
Patient 5
Visit Number Weight (lbs) Drug Dosage Prolactin
1 139.00 12.20
2 140.25 Aripiprazole 2.5 mg
3 139.25 Aripiprazole 1.25 mg
4 139.00 Aripiprazole 1.25 mg
5 135.50 Aripiprazole 2.5 mg 10.20
Patient 9
Visit Number Weight (lbs) Drug Dosage Prolactin
1 232.00 Haloperidol 4 mg,
Clonidine 0.2 mg
14.10
2 231.00 Aripiprazole 1.25 mg,
Haloperidol 4 mg
3 235.00 Aripiprazole 2.5 mg,
Haloperidol 3 mg
4 234.00 Aripiprazole 2.5 mg,
Haloperidol 2 mg
5 241.00 Aripiprazole 3.75 mg,
Haloperidol 1 mg
6 239.00 Aripiprazole 5.0 mg
7 236.00 Aripiprazole 6.25 mg
8 Aripiprazole 7.5 mg 14.90
Patient 10
Visit Number Weight (lbs) Drug Dosage Prolactin
1 112.00 Clonidine 0.4 mg 17.30
2 111.00 Aripiprazole 1.25 mg,
Clonidine 0.05 mg
3 109.50 Aripiprazole 2.5 mg
4 111.50 Aripiprazole 2.5 mg
5 113.50 Aripiprazole 2.5 mg
6 114.00 Aripiprazole 2.5 mg
7 Aripiprazole 2.5 mg
8 Aripiprazole 2.5 mg 0.80
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